
La Jolla Pharmaceutical Company LJPC
La Jolla Pharmaceutical Company Gross Profit | LJPC
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit La Jolla Pharmaceutical Company
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 25.6 M | 20.7 M | 8.41 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.6 M | 8.41 M | 18.2 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbbVie
ABBV
|
12.1 B | $ 263.04 | 0.49 % | $ 465 B | ||
|
Фармсинтез
LIFE
|
160 M | - | - | - | ||
|
Aclaris Therapeutics
ACRS
|
172 K | $ 5.53 | 6.02 % | $ 678 M | ||
|
Amryt Pharma plc
AMYT
|
116 M | - | - | $ 621 M | ||
|
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | ||
|
Chimerix
CMRX
|
212 K | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
7.9 K | - | - | $ 401 M | ||
|
ADMA Biologics
ADMA
|
293 M | $ 8.61 | 0.16 % | $ 2.05 B | ||
|
Guardion Health Sciences
GHSI
|
5.39 M | - | -0.31 % | $ 3.64 M | ||
|
Genocea Biosciences
GNCA
|
1.36 K | - | -15.0 % | $ 3.04 M | ||
|
Intercept Pharmaceuticals
ICPT
|
248 M | - | - | $ 643 M | ||
|
Intra-Cellular Therapies
ITCI
|
91.4 K | - | - | $ 13.6 B | ||
|
Chinook Therapeutics
KDNY
|
17.3 M | - | - | $ 2.6 B | ||
|
Kaleido Biosciences
KLDO
|
975 K | - | -3.69 % | $ 12.4 M | ||
|
LogicBio Therapeutics
LOGC
|
3.45 M | - | - | $ 229 M | ||
|
Lumos Pharma
LUMO
|
936 K | - | - | $ 35.3 M | ||
|
Merrimack Pharmaceuticals
MACK
|
137 M | - | - | $ 216 M | ||
|
Mirati Therapeutics
MRTX
|
3.03 M | - | - | $ 3.3 B | ||
|
9 Meters Biopharma
NMTR
|
-64 K | - | -42.97 % | $ 1.05 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
1 K | - | -19.68 % | $ 18.4 M | ||
|
Oncternal Therapeutics
ONCT
|
3.38 M | - | -24.12 % | $ 1.56 M | ||
|
Opiant Pharmaceuticals
OPNT
|
23.4 M | - | - | $ 109 M | ||
|
Orchard Therapeutics plc
ORTX
|
1.74 M | - | 1.02 % | $ 90.8 M |